LOS ANGELES--(BUSINESS WIRE)---- $NAGE #ClinicalResearch--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces it is the headlining sponsor of the inaugural NAD for Health: Opportunities & Challenges scientific meeting hosted by the University of Copenhagen, taking place March 23–25, 2026 at the Royal Danish Academy of Sciences and Letters in central Copenhagen. Space is limited and registration ...

Core Viewpoint - Celularity Inc. has successfully closed a financing transaction, enhancing its financial position and supporting its strategic initiatives in regenerative and cellular medicine [1][4]. Financing Details - Celularity received $10.00 million in gross proceeds from the financing, with the potential for an additional $2.0 million based on specific conditions [2]. - The financing structure includes a senior secured term loan of $7.0 million and secured convertible notes with commitments of up to $5.0 million, convertible at a price of $1.66 per share [3]. - The secured convertible notes are backed by a first-priority lien on proceeds from a qualified financing, and Celularity issued warrants for 3,707,657 shares of Class A Common Stock with an exercise price of $2.00 per share [3]. Strategic Focus - The company aims to leverage its placental-derived platform to address significant unmet medical needs related to healthy aging and performance optimization [4]. - Celularity plans to articulate its corporate strategy in the upcoming year, aligning its scientific capabilities with long-term opportunities in longevity and age-related diseases [5]. Company Overview - Celularity Inc. specializes in developing, manufacturing, and commercializing advanced biomaterial products and cell therapies derived from postpartum placenta, targeting fundamental aging mechanisms [7].

Core Viewpoint - Niagen Bioscience, Inc. has raised its full-year 2025 net sales outlook to a growth rate of 25% to 30% year-over-year, up from a previous estimate of 22% to 27% [1] Company Summary - Niagen Bioscience, Inc. is recognized as a global authority on NAD+ (nicotinamide adenine dinucleotide) and focuses on the science of healthy aging [1] - The company emphasizes the importance of elevating NAD+ levels for health, particularly as individuals age, highlighting the significance of this area of science for public health [1]

Core Insights - Niagen Bioscience, Inc. (NASDAQ: NAGE) is recognized as a global authority on NAD+ and focuses on the science of healthy aging [1] - The company has launched an evolved version of AboutNAD, which serves as a centralized educational resource and research database on NAD+ biology and its implications for human health [1] - The mission of the new platform is to empower health through scientific education by providing distilled peer-reviewed findings [1]

Core Insights - Jupiter Neurosciences, Inc. is advancing its proprietary resveratrol-based platform, JOTROL, which offers significant advantages over traditional resveratrol formulations [1][3][10] - JOTROL has demonstrated a nine-fold increase in bioavailability compared to conventional resveratrol, while avoiding gastrointestinal side effects [3][7][10] - The company is progressing JOTROL towards a Phase IIa trial for Parkinson's Disease, supported by promising preclinical data [4][8][10] Scientific and Clinical Advantages - Resveratrol is known for its antioxidant, mitochondrial, and anti-inflammatory properties, but its therapeutic use has been limited due to poor bioavailability and GI side effects [2][9] - JOTROL promotes mitochondrial biogenesis and reduces neuroinflammation, addressing key factors in neurodegenerative diseases and aging [5][6] Product Development and Market Strategy - JOTROL is not only aimed at pharmaceutical applications but also serves as the foundation for the Nugevia consumer product line, targeting cognitive health, mitochondrial energy, and skin vitality [4][11] - The Nugevia product line is set to launch in Q3 2025, leveraging the same delivery technology as JOTROL to provide clinical-grade bioavailability in the wellness market [11] Intellectual Property and Market Potential - The company has secured intellectual property rights for JOTROL in major markets including the U.S., EU, China, Japan, and Hong Kong, valid through 2036 [7] - JOTROL's ability to cross the blood-brain barrier positions it as a potential treatment for CNS disorders such as Parkinson's and Alzheimer's [7][8]

Core Points - Jupiter Neurosciences, Inc. has regained compliance with Nasdaq's minimum share price requirement, confirming an average closing share price of at least $1.00 for 13 consecutive days [1][2] - The company is focused on developing JOTROL, a patented resveratrol-based platform, targeting neuroinflammation and promoting healthy aging [3] Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company with a dual-path strategy addressing central nervous system (CNS) disorders and rare diseases, while also entering the consumer longevity market with its Nugevia product line [3] - The therapeutic pipeline includes a Phase IIa trial for Parkinson's disease and targets conditions such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS [3]

Summary of Biotechnology Management Presentation Company Overview - **Company Name**: Bio Techne - **Headquarters**: Minneapolis - **Employees**: Approximately 3,100 across 34 global locations - **Industry**: Biotechnology, focusing on protein-based reagents and products Core Business Segments - **Segments**: - Protein Sciences - Diagnostics and Spatial Biology - **Revenue Breakdown (2024)**: - Total Revenue: $1.2 billion - 80% from consumables - 9% from instrumentation - 9% from services related to instrumentation - 2% from royalties - **Revenue Composition**: - 72% from Protein Sciences - 28% from Diagnostics and Spatial Biology, which has grown from 26% the previous year [8][9][10] Growth Factors and Market Trends - **Key Growth Areas**: - Discovery of novel biological insights - Development and manufacturing of advanced therapeutics - Enablement of precision diagnostics - **Market Trends**: - Multiomic insight generation - AI-enabled innovation - Novel therapeutic approaches like cell therapy - Precision medicine and healthy aging [16][18][19] Financial Performance - **Recent Growth**: - 1% growth during a challenging period, with a return to 6% organic growth year-to-date for fiscal year 2025 [34] - **Operating Margins**: - Targeting 35-40% EBITDA range, with a historical CAGR of 40% [34][45] - **Market Position**: - Positioned to outgrow the overall market by 500 to 1,000 basis points [44] Innovations and Product Development - **Recent Launches**: - LEO instrument for high-throughput western blotting - Multi-omic solutions for RNA and protein visualization - ESR1 kit for breast cancer management [26][29][31] - **Acquisitions**: - Focus on M&A to enhance product offerings and market position, particularly in high-margin or high-growth companies [36] Sustainability and Corporate Governance - **Sustainability Initiatives**: - Published fourth corporate sustainability report, focusing on reducing waste and improving environmental footprint [42] - **Diversity and Inclusion**: - Commitment to a diverse and inclusive workplace [43] Conclusion - **Strategic Position**: - Bio Techne has built a differentiated proteomic core portfolio over 48 years, addressing a $28 billion market opportunity with a strong innovation pipeline [44] - **Future Aspirations**: - Aim for sustainable financial performance while unlocking scientific possibilities [45]